Abstract
Study Objectives Sleep interventions targeting slow-wave activity (SWA) show heterogeneous effects across individuals. We investigated whether pre-sleep brain states predict responsiveness to auditory stimulation and associated cognitive benefits.
Methods Twenty-eight healthy adults (19-40 years) completed three overnight laboratory visits under mild sleep restriction. Pre-sleep EEG recordings captured spectral band power before each night. Participants received auditory stimulation or sham on two randomized nights with polysomnography monitoring. Memory recall and sustained attention were assessed at multiple timepoints the following day. Machine learning models using normalized EEG features and transfer learning with pre-trained sleep architectures (SleepNet, DeepSleepNet, TinySleepNet) predicted responsiveness.
Results Auditory stimulation significantly enhanced SWA (p < 0.01) in over 90% of participants. Pre-sleep alpha and theta power correlated with SWA enhancement (alpha: r = 0.436; theta: r = 0.329; both p < 0.01), as did sleep onset latency (r = 0.429, p < 0.01). Temporal embeddings derived from 8 minutes of pre-sleep EEG before lights off predicted individual responsiveness to auditory stimulation with 80% accuracy (AUC = 0.93).
Conclusions Pre-sleep brain state determines responsiveness to auditory stimulation, with individuals exhibiting longer sleep onset latency showing greater SWA enhancement. Tailoring pre-sleep interventions based on these predictive features may optimize brain receptivity to auditory stimulation during sleep.
Competing Interest Statement
KP, PZ, AL, and GC own stock in, and are advisors to, NextSense, Inc., which partially funded this research study. The terms of this arrangement have been reviewed and approved by Emory University in accordance with Emory University Policy 7.7, Policy for Investigators Holding a Financial Interest in Research. PZ and KP have a patent for the phase-locking technique used in this manuscript with the United States Patent and Trademark Office (U.S. Patent Application No. 62/038,700). JB is the CEO of NextSense, Inc. AXS is an employee of NextSense, Inc. and received a salary for his work. The remaining authors have no conflicts of interest to declare.
Funding Statement
YK, AL, and GC acknowledge support from the Alzheimers Association, The Michael J. Fox Foundation for Parkinsons Research, and CurePSP Sleep Contributions to Neurodegeneration Grant Program (SCN- 25-1470707).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Northwestern University Institutional Review Board approved this study (Protocol STU00204417), and all participants provided informed consent prior to participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
6 Data Availability
All data produced in the present study are available upon reasonable request to the authors.
